NASDAQ:GHRS GH Research (GHRS) Stock Price, News & Analysis $12.49 +0.68 (+5.76%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$11.49▼$12.8850-Day Range$10.98▼$14.8152-Week Range$5.05▼$14.99Volume46,365 shsAverage Volume32,691 shsMarket Capitalization$649.85 millionP/E RatioN/ADividend YieldN/APrice Target$36.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get GH Research alerts: Email Address GH Research MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside193.6% Upside$36.67 Price TargetShort InterestBearish4.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.84) to ($1.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.57 out of 5 starsMedical Sector719th out of 936 stocksPharmaceutical Preparations Industry336th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingGH Research has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGH Research has only been the subject of 2 research reports in the past 90 days.Read more about GH Research's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.80% of the float of GH Research has been sold short.Short Interest Ratio / Days to CoverGH Research has a short interest ratio ("days to cover") of 28.9, which indicates bearish sentiment.Change versus previous monthShort interest in GH Research has recently increased by 8.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGH Research does not currently pay a dividend.Dividend GrowthGH Research does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GHRS. Previous Next 2.4 News and Social Media Coverage News SentimentGH Research has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for GH Research this week, compared to 1 article on an average week.Search Interest1 people have searched for GHRS on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GH Research insiders have not sold or bought any company stock.Percentage Held by Insiders41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GH Research's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for GH Research are expected to decrease in the coming year, from ($0.84) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GH Research is -20.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GH Research is -20.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGH Research has a P/B Ratio of 2.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about GH Research's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.Click here to learn more. About GH Research Stock (NASDAQ:GHRS)GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Read More GHRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GHRS Stock News HeadlinesJuly 19, 2024 | seekingalpha.comGHRS GH Research PLCJuly 6, 2024 | investorplace.com3 Psychedelic Stocks to Ride to the Moon and BeyondJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."May 10, 2024 | finance.yahoo.comWall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should KnowMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for GH Research Amid Promising Trials and Regulatory MilestonesMay 3, 2024 | investorplace.comGHRS Stock Earnings: GH Research Beats EPS for Q1 2024May 3, 2024 | globenewswire.comGH Research Reports First Quarter 2024 Financial Results and Provides Business UpdatesApril 26, 2024 | bizjournals.comMGB expands effort to make medical research more sustainableJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."April 26, 2024 | msn.comGH Video Preview: Gregory in Trouble, Joss Tells Jason She Did Something She RegretsApril 18, 2024 | yahoo.comGeneral Hospital Video Preview: Is Cyrus the Key to Bringing Down Sonny?April 17, 2024 | yahoo.comGH Spoilers Weekly Preview Video: It’s Sonny Corinthos Versus the WorldMarch 17, 2024 | yahoo.comGeneral Hospital Video Preview: Misdirections, Maladies, and MisdiagnosesMarch 15, 2024 | yahoo.comGeneral Hospital Video Preview: Catastrophic Thoughts Plague Jason and SonnyMarch 15, 2024 | yahoo.comThe General Hospital Coming Out Storyline Nobody Saw ComingMarch 4, 2024 | markets.businessinsider.comBuy Rating for GH Research: Promising Clinical Trials and Strategic Intellectual Property AdvancesMarch 1, 2024 | markets.businessinsider.comBuy Rating Justified by GH Research’s Promising Clinical Trials and Strong Financial HealthMarch 1, 2024 | msn.comGH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business UpdatesSee More Headlines Receive GHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/03/2024Today7/26/2024Next Earnings (Estimated)8/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GHRS CUSIPN/A CIK1855129 Webwww.ghres.com Phone212-450-4000FaxN/AEmployees49Year FoundedN/APrice Target and Rating Average Stock Price Target$36.67 High Stock Price Target$40.00 Low Stock Price Target$31.00 Potential Upside/Downside+193.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-14.56% Return on Assets-14.10% Debt Debt-to-Equity RatioN/A Current Ratio22.06 Quick Ratio22.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book2.53Miscellaneous Outstanding Shares52,028,000Free Float30,384,000Market Cap$649.83 million OptionableOptionable Beta0.86 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Florian Schonharting M.Sc. (Econ) (Age 55)Co-Founder & Non-Executive Chairman of the Board Dr. Theis Terwey M.D. (Age 48)Co-Founder & CEO Mr. Magnus Halle (Age 27)Co-Founder & MD of Ireland Ms. Julie Ryan F.C.A. (Age 38)Vice President of Finance Mr. Aaron Cameron M.B.A. (Age 39)Chief Operating Officer Mr. Naoise GaffneyVP & Head of Intellectual PropertyDr. Velichka Valcheva M.D. (Age 49)Chief Medical Officer More ExecutivesKey CompetitorsCastle BiosciencesNASDAQ:CSTLRevance TherapeuticsNASDAQ:RVNCAtai Life SciencesNASDAQ:ATAISangamo TherapeuticsNASDAQ:SGMOPMV PharmaceuticalsNASDAQ:PMVPView All CompetitorsInstitutional OwnershipLynx1 Capital Management LPBought 1,471,946 shares on 5/30/2024Ownership: 6.363%RA Capital Management L.P.Bought 664,381 shares on 5/17/2024Ownership: 12.016%PEAK6 Investments LLCBought 6,100 shares on 5/15/2024Ownership: 0.000%View All Institutional Transactions GHRS Stock Analysis - Frequently Asked Questions How have GHRS shares performed this year? GH Research's stock was trading at $5.80 at the beginning of the year. Since then, GHRS shares have increased by 115.3% and is now trading at $12.49. View the best growth stocks for 2024 here. How were GH Research's earnings last quarter? GH Research PLC (NASDAQ:GHRS) posted its quarterly earnings data on Friday, May, 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. When did GH Research IPO? GH Research (GHRS) raised $150 million in an initial public offering on Friday, June 25th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of GH Research? Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GHRS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GHRS Stock Alerts